Type 2 diabetes
Conditions
Interventions
In the first course, insulin glargine U100 is used for 4 weeks. After the treatment of insulin glargine U100, the CGM examination is underwent. In the second course, insulin glargine U300 is used for
Sponsors
Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetic patient who has injected glargine U100 for more than 12 weeks. 2) HbA1c less than 9% within 4 weeks prior to entry 3) Patient who can undergo self monitoring blood glucose before each insulin injection and equip continuous glucose monitoring
Exclusion criteria
Exclusion criteria: 1) severe ketosis, coma, or reduced level of con- sciousness due to diabetes within the past 6 months 2) Patients who may have been pregnant or pregnant women 3) Patients with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) 4) Patients with moderate or severe renal dysfunction (BUN more than 25mg/dL or serum creatinine more than 2.0 mg/dL)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average of 2 times of mean of daily differences (MODD) | — |
Secondary
| Measure | Time frame |
|---|---|
| Day-by-day variability of fasting blood glucose | — |
Countries
Japan
Contacts
Public ContactMasaya Sakamoto
Jikei University School of Medicine Division of Diabetes, Metabolism and Endocrinology
Outcome results
None listed